Highlights of the Investigation
Exposure to antipsychotic medication in critically ill patients is associated with a 74% reduction in the odds of experiencing more catatonia-free days within the first five days of ICU admission.
A clear dose-response relationship was observed, where patients receiving higher dosages of antipsychotics faced a 97% reduction in the odds of remaining alive and free from catatonia.
The findings provide strong clinical evidence supporting the hypothesis that dopamine blockade is a central biological mechanism underlying catatonia in the context of critical illness.
The Hidden Burden of Catatonia in the Intensive Care Unit
Catatonia is a complex neuropsychiatric syndrome characterized by motor abnormalities, such as immobility or excessive motor activity, mutism, and withdrawal. While historically associated with primary psychiatric disorders like schizophrenia or bipolar disorder, catatonia is increasingly recognized as a frequent occurrence in the intensive care unit (ICU). Despite its prevalence, the underlying causal mechanisms of catatonia in the critically ill remain poorly understood, leading to challenges in both diagnosis and management.
In many ICU settings, delirium and catatonia coexist or are mistaken for one another. Paradoxically, the very medications often used to manage the agitation associated with delirium—antipsychotics—rely on dopamine receptor blockade, which is a known risk factor for inducing catatonic symptoms. This creates a clinical dilemma for intensivists: the use of neuroleptics to control behavior may inadvertently exacerbate or trigger a catatonic state, thereby prolonging the duration of critical illness and mechanical ventilation.
Methodology: The Delirium and Catatonia Prospective Cohort Investigation
To address this clinical uncertainty, the Delirium and Catatonia Prospective Cohort Investigation was conducted at a single academic medical center. The study focused on medical, surgical, and trauma ICU patients. The researchers aimed to determine if antipsychotic exposure—specifically its presence and cumulative dosage—influenced the number of days patients remained alive and free from catatonia.
Patient Population
The cohort included 270 critically ill adult patients. Eligibility required patients to be on mechanical ventilation or vasopressors, ensuring the inclusion of those with high severity of illness. To maintain the integrity of the findings, the researchers excluded patients with pre-existing major neurocognitive disorders, severe psychiatric disorders (such as schizophrenia), or those who exhibited catatonia at the baseline of the study.
Interventions and Measurements
The primary exposure was the administration of antipsychotic medication and the cumulative dosage during two specific timeframes: the first 5 days and the first 14 days from enrollment. The primary outcome was catatonia-free days (CFDs), a composite measure representing the number of days a patient was both alive and free from the syndrome. Catatonia was rigorously evaluated using the Bush-Francis Catatonia Rating Scale, which was mapped to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.
Analyzing the Results: A Strong Association with Antipsychotic Exposure
The results of the study were striking and suggested a potent link between dopamine-blocking agents and the development of catatonia. Out of the 102 patients exposed to antipsychotic medication, 27 (26%) experienced catatonia during their ICU stay.
Primary Outcome: Catatonia-Free Days
Using adjusted proportional odds logistic regression to control for confounders, the researchers found that patients exposed to antipsychotics had significantly worse outcomes. In the 5-day model, exposure was associated with a 74% reduction in the odds of having more catatonia-free days (OR, 0.2568; 95% CI, 0.1580-0.4173). In the 14-day model, the association remained significant, with a 51% reduction in the odds of more CFDs (OR, 0.4939; 95% CI, 0.3857-0.6325).
The Dose-Response Relationship
Perhaps the most compelling evidence from this study was the dose-response relationship. Patients exposed to higher cumulative dosages of antipsychotics faced a 97% reduction in the odds of more CFDs compared to those on lower dosages in both the 5-day (OR, 0.0281) and 14-day (OR, 0.0335) models. This suggests that the risk of catatonia is not merely binary based on exposure, but scales significantly with the intensity of dopamine blockade.
Mechanistic Insights: The Role of Dopamine Blockade
The biological plausibility of these findings is rooted in the neurobiology of the basal ganglia and the mesocorticolimbic pathways. Catatonia is thought to involve a sudden and massive reduction in dopamine activity, particularly at the D2 receptors. Antipsychotics, which primarily function as D2 receptor antagonists, directly inhibit dopaminergic neurotransmission. In the vulnerable environment of critical illness—where systemic inflammation, metabolic derangements, and sedative use already compromise neurochemical balance—the addition of a dopamine-blocking agent may reach a threshold that precipitates catatonia.
This study reinforces the theory that ‘neuroleptic-induced catatonia’ is a significant risk in the ICU. It suggests that while antipsychotics may settle an agitated patient, they may also be inducing a state of motor and cognitive ‘stuckness’ that mimics or exacerbates the underlying critical illness.
Clinical Implications for the Intensivist
These findings should prompt a re-evaluation of how antipsychotics are utilized in the ICU. For years, antipsychotics like haloperidol or quetiapine have been the first-line response to ICU delirium, despite varying evidence of their efficacy in shortening delirium duration. This study suggests that clinicians must be highly vigilant for catatonic signs before and during antipsychotic therapy.
Recommendations for Practice:
1. Routine Screening: Utilize tools like the Bush-Francis Catatonia Rating Scale for patients who exhibit unexpected mutism, immobility, or refusal to eat, rather than assuming it is purely hypoactive delirium.
2. Judicious Prescribing: Use the lowest possible dose of antipsychotics when they are absolutely necessary for patient safety, and consider non-pharmacological interventions for delirium management first.
3. Consider Alternatives: In patients showing early signs of catatonia, benzodiazepines (such as lorazepam) or electroconvulsive therapy (ECT) are the established treatments, whereas antipsychotics are generally contraindicated.
Conclusion and Summary
The study by Mina et al. provides a critical piece of the puzzle regarding neuropsychiatric outcomes in the ICU. By demonstrating a significant association between antipsychotic exposure and a decrease in catatonia-free days, the research highlights a potentially modifiable risk factor for one of the most debilitating syndromes in critical care. As the medical community moves toward more personalized and evidence-based sedation and delirium protocols, the role of dopamine blockade must be carefully weighed against the risk of inducing catatonia. Future research should focus on whether the cessation of antipsychotics at the first sign of catatonic features can reverse the syndrome and improve long-term cognitive outcomes for ICU survivors.
References
1. Mina GN, McGonigle T, Liu J, et al. Exposure to Antipsychotic Medication Is Associated With Less Days Alive and Free From Catatonia in Critically Ill Patients. Critical Care Medicine. 2026. PMID: 41805231.
2. Pandharipande PP, Ely EW, Arora RC, et al. The American Society of Health-System Pharmacists, Society of Critical Care Medicine, and American College of Clinical Pharmacy Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018.
3. Smith JR, et al. Catatonia in the ICU: An under-recognized entity. Journal of Intensive Care Medicine. 2024.